Enterprise Value

1.982B

Cash

343.9M

Avg Qtr Burn

N/A

Short % of Float

36.03%

Insider Ownership

18.88%

Institutional Own.

90.11%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

WAKIX® (pitolisant) Details
EDS in Idiopathic Hypersomnia

Phase 3

Data readout

Phase 3

Update

WAKIX® (pitolisant) Details
Muscle degeneration, Muscle weakness

Phase 2

Data readout

WAKIX® (pitolisant) Details
Genetic disorder, Rare genetic disease, Prader-Willi syndrome

Phase 2

Data readout